Skip to main content
Clinical Trials/NCT06951451
NCT06951451Not yet recruitingNot Applicable

Effect of Smartphone Application (MED-AD) on Medication Adherence Among Patients With Cardiovascular Disease in Oman: A Multicenter Randomized Clinical Trial

Sultan Qaboos University1 site in 1 country1,000 target enrollmentStarted: June 1, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
1,000
Locations
1
Primary Endpoint
Adherence to Refills and Medications Scale

Study Overview

Brief Summary

This study aims to:

  1. Investigate the impact of MED-AD intervention on medication adherence among CVD patients, compared to patients receiving text message reminders or routine care alone at baseline, 6 months, and 12 months later.
  2. Evaluate the effectiveness of MED-AD intervention on clinical outcomes among patients with CVD, compared to the outcomes of patients receiving text or routine care alone at baseline, 6 months, and 12 months later.

This study is a prospective randomized controlled clinical trial (RCT) with three arms:

  1. MED-AD intervention: MED-AD is a smartphone application that will use the following strategies (pill reminders, Medication Adherence Report, medication intake confirmation, Medical Appointment Reminder, and educational notifications) to enhance medication adherence
  2. Text message reminders: Participants will receive short text message (SMS) reminders to remind them to take medications as prescribed once daily
  3. Routine care only: Participants will receive routine care that does not include text messages or reminders and education through an application.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Single (Care Provider)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •diagnosed with at least one CVD (i.e., HTN, IHD, hyperlipidemia),
  • •prescribed at least one medication for at least one year,
  • •Omanis aged 18 years or older,
  • •registered in the selected healthcare center, and 5) agreed to participate in the study

Exclusion Criteria

  • •have a severe cognitive impairment,
  • •are unable to provide informed consent,
  • •cannot read, and 4) do not have a smartphone with a compatible operating system (ios or Android).

Arms & Interventions

MED-AD application

Experimental

MED-AD is a smartphone application that will use two strategies (pill reminders and educational notifications) to enhance medication adherence. Both methods have shown their effectiveness in independently improving medication adherence; however, combining two or more strategies maximizes the efficacy of improving adherence. In addition, this application will be unique as it allows the patient to engage with their self-management behaviors and get feedback about their performance. The research team will develop the smartphone application with an expert in the application development field. In addition, the research team will pilot the MED-AD application on the same population and modify it before implementation of the study. The application will be hosted on SQU's in-house data, which is hosted and managed by the Center for Information Systems.

Intervention: smartphone application (MED-AD) (Behavioral)

Short Text-message Reminders

Active Comparator

Participants will receive short text messages (SMS) to remind them to take medications as prescribed once daily. However, unlike the application reminders, the SMS will be general and not specify taking particular medicines. An example of the SMS message will be, "Remember to take your medicines for the day?" The research team will pilot the MED-AD application on the same population and modify it before implementing the study.

Intervention: Short Text-message Reminders (Behavioral)

Routine care

No Intervention

Participants will receive routine care that does not include text messages or reminders and education through an application. In primary health care centers, the current routine care for people with chronic disease consists of the physical attendance of patients to their pre-scheduled medical appointment. The medical appointment will be every three months for most regular and controlled cases. The health care provider will usually evaluate the patient's condition, including the disease progression and medication adherence, and compare that with clinical parameters and laboratory investigations. Medications will be prescribed for the next three months, but the dispensing will be monthly. Patients will come every month directly to the pharmacy for a medication refill. The pharmacist will check the time window for medication refills and dispense the prescribed medications for one month.

Outcomes

Primary Outcomes

Adherence to Refills and Medications Scale

Time Frame: BASELINE, AT 6 MONTHS, AT 12 MONTHS

This instrument includes 12 items divided into two subscales: 8 items on the medication-taking subscale and four items on the refill subscale. The items are scored on a 4-point Likert scale with ranges of 1 = ''none of the time'' to 4 = ''all of the time.'' The total score is the sum of all items, ranging from 12 to 48, with lower scores representing better medication adherence.

The Proportion of Days Covered

Time Frame: BASELINE, AT 6 MONTHS, AT 12 MONTHS

This measure is one of the objective, indirect instruments used to measure adherence. It calculates the number of days "covered" over the total number of days in the same period. Proportion of days covered = Days Supply of medication dispensed to the patient/ Total number of days X 100% The scoring is always positive and ranges from 0 to 100%. Zero means no adherence, while a PDC of 100% indicates perfect adherence. The threshold is the level that provides a reasonable likelihood of achieving the clinical benefits of therapy. For patients with cardiovascular diseases (CVD), clinical evidence supports using 80% as a standard PDC threshold.

Secondary Outcomes

  • Clinical outcomes(BASELINE, AT 6 MONTHS, AT 12 MONTHS)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dr. Huda Al Noumani

Associate Professor, Department of Adult Health and Critical Care

Sultan Qaboos University

Study Sites (1)

Loading locations...

Similar Trials